Clinical trial

Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension

NCT04218552

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-02-25

PhasePHASE2

Study timeline

Study start (actual)2020-02-25Date precision: day

Registry last updated2021-07-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Hypertension,Essentialunresolved

Interventions

AD209DRUG

Amlodipine lowDRUG

Amlodipine highDRUG

TelmisartanDRUG · verified · RxNorm: telmisartan

Sponsors & collaborators

Addpharma Inc.lead sponsor

Mapped research locations

SeoulSouth Korea1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04218552 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.